This clinical trial will include advanced/relapsed ovarian, breast, pancreatic, and prostate cancer patients who can be treated with PARPis and HER2-negative breast cancer patients with BRCA1/2, PALB2, RAD51C, and RAD51D mutations. The gene discussed is PALB2; the disease is prostate carcinoma.